Abstract
Myasthenia gravis is an important indication for the long-term prescription of corticosteroids. We present a patient with myasthenia gravis who had worsening of symptoms associated with the use of alendronate. A 24-year-old patient with myasthenia gravis had been administered oral systemic corticosteroid (deflazacort 40 mg/day) for 3 years in order to control his myasthenic symptoms. One year earlier, his lumbar spine bone mineral density was decreased. He was started on oral calcium/vitamin D3 and alendronate (70-mg tablets once a week) for osteoporosis. He reported an exacerbation of muscle weakness and extreme fatigue on days when he took alendronate. He could not work on these days and has to be on leave. Alendronate was stopped, and he was started on intravenous ibandronate injections given every 3 months. He did not experience muscle weakness and fatigue with ibandronate therapy. Alendronate should be used with caution in patients with myasthenia gravis who have corticosteroid-induced osteoporosis.
References
Lewis SJ, Smith PE (2001) Osteoporosis prevention in myasthenia gravis: a reminder. Acta Neurol Scand 103:320–322
National guidelines for the prevention and management of corticosteroid induced osteoporosis. Bath: UK osteoporosis consensus group; 1998
Bone and Tooth Society (2002) National Osteoporosis Society, Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: RCP
Lozsadi DA, Peters G, Sadik HY, Kellett MW, Fox SH, Smith DF (2006) Prevention of osteoporosis in glucocorticoid-treated neurology patients. Clin Neurol Neurosurg 108:157–162
Wittbrodt ET (1997) Drugs and myasthenia gravis. An update. Arch Intern Med 157:399–408
Raja V, Sandanshiv P, Neugebauer M (2007) Risedronate induced transient ocular myasthenia. J Postgrad Med 53:274–275
Palin SL, Singh BM (2000) Primary hyperthyroidism due to a parathyroid adenoma with subsequent myasthenia gravis. QJM 93:560–561
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kesikburun, S., Güzelküçük, Ü., Alay, S. et al. Exacerbation of myasthenia gravis by alendronate. Osteoporos Int 25, 2319–2320 (2014). https://doi.org/10.1007/s00198-014-2768-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-014-2768-4